Patients no longer wait for geroscience to become standard medicine. They arrive with biological-age reports, supplement lists, podcast claims and questions about drugs that are approved for other conditions. Primary care is being asked to interpret a field that has not yet agreed on its clinical rules.
That is the problem raised by family physician Dean Ariel in a Nature Aging World View published August 25. The article is a commentary, not a randomized trial. Its value is diagnostic: longevity medicine has entered the exam room before medical training, guidelines and reimbursement have caught up.
Three different meanings of longevity medicine
Online, longevity medicine often means a package of testing, supplements and off-label prescriptions intended to optimize biological age. In research, geroscience asks whether targeting mechanisms of aging can delay several diseases or disabilities at once. In primary care, longevity usually means preventing known causes of early illness and preserving function.
Those worlds overlap, but they are not interchangeable. A mechanism that extends life in mice is not a treatment. A biomarker that predicts risk is not necessarily a validated target. A clinic that measures more variables is not automatically delivering better prevention.
The FDA states that no medication has been proven to slow or reverse the aging process. That does not mean aging biology is imaginary. The National Institute on Aging describes geroscience as a serious effort to translate mechanisms of aging into interventions and clinical trials. The gap lies between an active research program and routine care.
Biological-age tests create a new kind of uncertainty
Commercial epigenetic, proteomic and blood-based age tests can return a precise-looking number. Precision in the report does not guarantee clinical validity. Different clocks measure different patterns, can disagree about the same person, and may shift with cell composition or short-term conditions.
Most important, physicians often lack an evidence-based action tied to a change of several biological years. Repeating a test may create anxiety or optimization theater without improving care. Our analysis of aging clocks and interventions explains why responsiveness alone does not make a clock a validated surrogate for longer, healthier life.
The drugs patients are asking about
Rapamycin
Rapamycin extends lifespan in multiple animal models and has a compelling mechanistic foundation through mTOR. Human studies have explored immune function, skin and specific diseases, but routine off-label prescribing for healthy adults lacks definitive evidence for longer healthspan. Dose, schedule, infection risk, metabolic effects and drug interactions remain practical questions.
Metformin
Metformin is an established treatment for type 2 diabetes. Observational studies and mechanistic work made it a leading geroscience candidate, but healthier-user bias and differences between people with and without diabetes limit inference. A drug can be valuable for its approved indication without being proven as an anti-aging treatment for a healthy person.
Senolytics
Senolytics aim to remove senescent cells. Mouse data are extensive, and early human studies exist in specific conditions. The field has not established that currently marketed regimens safely extend healthspan in healthy adults. Intermittent dosing does not erase uncertainty about tissue effects, immune function or interactions.
Supplements and peptides
Supplements range from correcting a documented deficiency to speculative stacks. Quality, dose and interactions can be as important as mechanism. Peptide marketing is even harder to generalize because the category includes proven medicines and poorly studied compounds. Our Peptide Boom evidence guide separates approved uses from clinic claims.
What primary care can responsibly do today
The strongest longevity toolkit is familiar: control blood pressure and lipids when indicated, manage diabetes, stop smoking, update vaccinations, screen for cancers based on age and risk, preserve muscle and balance, support sleep and mental health, and help people sustain physical activity and a nutritious diet.
That can sound less exciting than a biological-age dashboard. It is also where randomized trials and clinical guidelines offer the clearest connection to fewer cardiovascular events, fractures, cancers and disability.
A responsible visit can go further without pretending certainty:
- Ask what outcome the patient wants, not only which intervention they saw online.
- Review the evidence by population, dose, comparator and duration.
- Check whether a proposed drug is approved, off-label or unapproved.
- Discuss opportunity cost, monitoring, interactions and financial incentives.
- Use conventional risk factors before ordering novel tests that lack an actionable pathway.
- Offer clinical-trial participation when an experimental intervention is the real goal.
Why primary care is structurally behind
Family physicians already manage multimorbidity in short visits. Longevity questions cut across cardiology, endocrinology, oncology, geriatrics, genetics and preventive care. Training materials are uneven, commercial claims change quickly, and insurers may not cover the time required to evaluate a stack of tests and off-label drugs.
Commercial longevity clinics fill that vacuum with longer appointments and coherent narratives. Some provide careful preventive care. Others bundle plausible mechanisms with weak endpoints, proprietary panels and products the clinic also sells. The conflict is not proof of bad medicine, but it should raise the standard for transparency.
A practical bridge from geroscience to the clinic
Primary care does not need to endorse every intervention to engage seriously. Medical societies and geroscience researchers can build living guidance that labels evidence by stage, explains which biomarkers are validated, lists monitoring needs for off-label use, and updates as trials report.
Researchers also need outcomes that clinicians can interpret. A change in a molecular clock is easier to measure than delayed disability, but a surrogate becomes useful only when changing it reliably predicts a meaningful benefit. Longer trials, diverse enrollment and transparent adverse-event reporting are essential.
Regulators face a related challenge because aging is a broad process rather than one conventional disease indication. Trials can still target frailty, immune response, organ function or clusters of age-related outcomes. The hard part is proving that a treatment improves how people feel, function or survive, not merely that it touches an aging pathway.
The consultation patients deserve
A good answer is neither dismissal nor a sales pitch. It can acknowledge that geroscience is moving quickly, explain what is known, protect against avoidable harm and revisit the decision when better data arrive. For some patients, the answer will be to treat a conventional risk factor more aggressively. For others, it may be enrollment in a legitimate trial. Often, it will be to wait.
Bottom line: Longevity medicine is already part of primary care because patients have brought it there. The responsible response is not to confuse emerging science with established treatment. It is to give clinicians the time, training and evidence framework to distinguish the two.
Sources: Nature Aging World View; FDA guidance on anti-aging medication claims; NIH Geroscience Interest Group